As competitors mounts within the red-hot marketplace for weight reduction medicine, France’s medicines regulator fined Novo Nordisk roughly $2 million for working “deceptive” ads for its Wegovy and Saxenda medicines.
On the similar time, the Nationwide Company for Medicines and Well being Merchandise Security additionally fined Eli Lilly roughly $127,000 over promoting for its Mounjaro weight problems therapy that purportedly amounted to oblique promotion of a medication for which a prescription is required.
The penalties replicate growing concern amongst regulators that weight reduction medicines could also be misused and, as outcome, promotions run by pharmaceutical corporations are being intently scrutinized. Two years in the past, the regulator issued a bulletin on the dangers related to the medicine, particularly inappropriate use.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans